Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The probability of response after each subcutaneous injection of esketamine in treatment-resistant depression.
Fava VAR, Sarin LM, Lucchese AC, Del Sant L, Magalhães E, Delfino RS, Tuena MA, Nakahira C, Jackowski AP, Abdo G, Surjan J, Steiglich M, Barbosa MG, Porto JAD, Lacerda ALT, Cogo-Moreira H. Fava VAR, et al. Among authors: surjan j. Rev Psiquiatr Salud Ment (Engl Ed). 2020 Oct 16:S1888-9891(20)30117-8. doi: 10.1016/j.rpsm.2020.10.003. Online ahead of print. Rev Psiquiatr Salud Ment (Engl Ed). 2020. PMID: 33075541 English, Spanish.
Effects of subcutaneous esketamine on blood pressure and heart rate in treatment-resistant depression.
Del Sant LC, Sarin LM, Magalhães EJM, Lucchese AC, Tuena MA, Nakahira C, Fava VAR, Delfino R, Surjan J, Steiglich MS, Barbosa M, Abdo G, Cohrs FM, Liberatori A, Del Porto JA, Lacerda ALT, de Jesus Mari J. Del Sant LC, et al. Among authors: surjan j. J Psychopharmacol. 2020 Oct;34(10):1155-1162. doi: 10.1177/0269881120922955. Epub 2020 Jul 8. J Psychopharmacol. 2020. PMID: 32638662
Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity.
Lucchese AC, Sarin LM, Magalhães EJM, Del Sant LC, B Puertas C, Tuena MA, Nakahira C, Fava VA, Delfino R, Surjan J, Steiglich MS, Barbosa M, Abdo G, Cohrs FM, Liberatori A, Del Porto JA, Lacerda AL, B Andreoli S. Lucchese AC, et al. Among authors: surjan j. J Psychopharmacol. 2021 Feb;35(2):142-149. doi: 10.1177/0269881120978398. Epub 2021 Jan 9. J Psychopharmacol. 2021. PMID: 33427015
A Clinical Rationale for Assessing the Impact of Childhood Sexual Abuse on Adjunctive Subcutaneous Esketamine for Treatment-Resistant Depression.
Magalhães EJM, Sarin LM, Del Sant LC, Lucchese AC, Nakahira C, Tuena MA, Puertas CB, Rodovalho Fava VA, Delfino RS, Surjan J, Steglich MS, Barbosa MG, Abdo G, Del Porto JA, Nemeroff CB, Cogo-Moreira H, Lacerda ALT, Mello AF. Magalhães EJM, et al. Among authors: surjan j. Front Psychiatry. 2021 Aug 17;12:608499. doi: 10.3389/fpsyt.2021.608499. eCollection 2021. Front Psychiatry. 2021. PMID: 34483976 Free PMC article.
The probability of response after each subcutaneous injection of esketamine in treatment-resistant depression.
Fava VAR, Sarin LM, Lucchese AC, Del Sant L, Magalhães E, Delfino RS, Tuena MA, Nakahira C, Jackowski AP, Abdo G, Surjan J, Steiglich M, Barbosa MG, Porto JAD, Lacerda ALT, Cogo-Moreira H. Fava VAR, et al. Among authors: surjan j. Rev Psiquiatr Salud Ment (Engl Ed). 2021 Oct-Dec;14(4):212-217. doi: 10.1016/j.rpsmen.2021.11.003. Rev Psiquiatr Salud Ment (Engl Ed). 2021. PMID: 34861929
Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression.
Surjan J, Grossi JD, Del Porto JA, Delfino RS, de Oliveira Cerqueira R, Lucchese AC, Magalhães E, Del Sant LC, Tuena MA, Nakahira C, Fava VAR, Steglich MS, Abdo GL, Barbosa MG, Sarin LM, Lacerda ALT. Surjan J, et al. Clin Drug Investig. 2022 Oct;42(10):865-873. doi: 10.1007/s40261-022-01193-z. Epub 2022 Aug 31. Clin Drug Investig. 2022. PMID: 36044154
19 results